Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system

With the increased use of immune checkpoint inhibitors (ICIs) in advanced lung cancer, adverse events (AEs), particularly immune-related AEs (irAEs), have garnered considerable interest. We conducted a comprehensive assessment of the toxicity profile in advanced lung cancer using multi-source medica...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi‐Dan Yan, Ying Zhao, Chi Zhang, Jie Fu, Ying-Jie Su, Xiangli Cui, Er-Li Ma, Bing-Long Liu, Zhi‐Chun Gu, Hou‐Wen Lin
Format: Artigo
Language:English
Published: 2022
Online Access:https://doi.org/10.1016/j.eclinm.2022.101535
http://www.thelancet.com/article/S2589537022002656/pdf
Tags: Add Tag
No Tags, Be the first to tag this record!